These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31043388)

  • 1. Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2019 May; 25(9):2940. PubMed ID: 31043388
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
    Long J; Zhao J; Yan Z; Liu Z; Wang N
    Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition.
    Ma J; Luo T; Zeng Z; Fu H; Asano Y; Liao Y; Minamino T; Kitakaze M
    Sci Rep; 2016 Sep; 6():34036. PubMed ID: 27667442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
    Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
    Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
    J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
    de Ruijter AJ; Kemp S; Kramer G; Meinsma RJ; Kaufmann JO; Caron HN; van Kuilenburg AB
    Biochem Pharmacol; 2004 Oct; 68(7):1279-88. PubMed ID: 15345317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
    Almotairy ARZ; Gandin V; Morrison L; Marzano C; Montagner D; Erxleben A
    J Inorg Biochem; 2017 Dec; 177():1-7. PubMed ID: 28918353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
    Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
    Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
    Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.